Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis

What Was Tested

This randomized controlled trial paper looks at Abaloparatide in the context of osteoporosis and bone density.

Advanced age is an important risk factor for fracture.

This study describes the effects of abaloparatide in the subgroup of women aged 80 or more years in ACTIVE.

Who Took Part

The age groups tagged for this paper are people over 80, women only.

Post hoc analyses of BMD and fracture incidence in this subgroup of women who received abaloparatide or placebo in the 18-month, phase 3, double-blind, randomized controlled ACTIVE trial.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Abaloparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Abaloparatide, so expectations could not easily colour the readings.

Some participants received a placebo instead of Abaloparatide, giving a reference point.

What Was Measured

PubMed files the paper under topics including Bone Density, Bone Density Conservation Agents, Femur Neck, Incidence, Lumbar Vertebrae, Osteoporosis, Postmenopausal and Osteoporotic Fractures.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Abaloparatide in people with osteoporosis and bone density.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Menopause (New York, N.Y.)), a journal based in United States.

More context: the Abaloparatide compound page, Osteoporosis and bone density research.